Stocks in play: Aeterna Zentaris Inc.

Provided a corporate update. CEO Klaus Paulini said, "Over the course of the last year since my appointment as CEO, a tremendous amount has been achieved. With the set intention to first assess and determine how best to support our current development partnership and how to maximize its success, followed by pursuing the expansion of macimorelin into pediatric use, I believe we are now well-positioned to advance Aeterna into its next phase of growth." Aeterna Zentaris Inc. shares T.AEZS are trading down $0.02 at $0.48.

Read:

• Health Crisis Has Created a Potential $250 Billion Telehealth Opportunity

• US FDA Starting to Grant Fast-Track Designation for Glioblastoma Treatments